Furthermore, treatment of wild-type mice with PACMA-31 (an orally active irreversible PDI inhibitor) in a model of ovalbumin (OVA)-induced food allergy resulted in a significant attenuation in the development of food allergy symptoms including decreases in allergic diarrhea, mast cell activation and allergen-specific IgE. This evidence concerns the gene IGHE and food allergy.